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ABSTRACT 
The present work was investigated to reduce the dosing frequency, improve patient compliance, to improve gastric residence and to decrease GI side effects by 
designing  and  evaluating  controlled  Release  Mucoadhesive  (CRM)  microbeads  of  Metformin  hydrochloride  for  effective  control  of  diabetes  type-II. 
Microbeads were prepared by employing ionic gelation method by using various natural and synthetic polymers such as sodium alginate as main polymer and 
sodium carboxy methyl cellulose(SCMC), carboxy methyl cellulose(CMC), methyl cellulose (MC), poly vinyl pyrrolidine (PVP) as co-polymers which mainly 
containing mucoadhesive property. These polymers are used with various proportions using calcium chloride as across linking agent. The mucoadhesive 
property of  four polymers is in the  following order (SCMC > CMC >  MC > PVP).Twenty  formulations  were prepared. The  mucoadhesive beads  were 
characterized for micromeritic properties such as bulk density, tapped density, hausner’s ratio, compressibility index, angle of repose, percentage drug content, 
entrapement effieciency, swelling index, In-vitro drug release, mucoadhesion test, drug kinetics and FT-IR studies. The drug entrapment efficiency increased 
progressively with increasing  concentration of  co -  polymer resulting in  the formation of larger microbeads entrapping greater amounts of the drug. No 
significant drug-polymer interactions were observed in FT-IR studies. The kinetics of drug release and their mucoadhesive nature in vitro using goat intestinal 
mucosa was also investigated at physiological pH 1.2 HcL. The effective mucoadhesion property with controlled release profile was observed from optimized 
mucoadhesive beads consisting of Sodium alginate and SCMC (1:5). The prepared microspheres exhibited prolonged drug release as the concentration of co-
polymer increased, as the SCMC polymer concentration increases the mucoadhesion increased and the drug release rate decreased at higher concentration of 
sodium alginate. 
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INTRODUCTION 
The concept of the advanced drug delivery systems especially 
those  offering a sustained and controlled action of drug to 
desired area of effect, attained great appeal for nearly half a 
century. Sustained release or prolonged release dosage forms 
are  designed  to  achieve  prolonged  therapeutic  effect  by 
continuously releasing the drug over an extended period of 
time after administration of single dose. Since the frequency 
of drug administration is reduced, patient compliance can be 
improved and the frequency  of drug administration can be 
made more convenient as well. The blood level oscillation 
characteristic of multiple dosing of conventional dosage form 
is reduced. 
Further,  the  process  of  targeting  and  site  specific  delivery 
with  absolute  accuracy  can  be  achieved  by  attaching 
bioactive  molecule  to  liposome’s,  bio-  erodible  polymer, 
implants,  monoclonal  antibodies  and  various  particulate 
carriers (E.g., nanoparticles and microspheres / microbeads, 
etc.). The micro particulate delivery systems are considered 
and accepted as a reliable means to deliver the drug to the 
target site with specificity, if modified, and to maintain the 
desired concentration at the site of interest without untoward 
effects. Mucoadhesive systems permit a given drug delivery 
system to be incorporated with bio / mucoadhesive agents, 
enabling the device to adhere to the stomach (or other GI) 
walls, thus resisting gastric emptying. A bio / mucoadhesive 
substance  is  a  natural  or  synthetic  polymer.  The 
characteristics  of  these  polymers  are  molecular  flexibility, 
hydrophilic functional groups, and specific molecular weight, 
chain length, and conformation. Furthermore, they must be 
nontoxic and non - absorbable.  
Mucoadhesive drug delivery systems interact with the mucus 
layer  covering  the  mucosal  epithelial  surface,  and  mucin 
molecules and increase the residence time of the dosage form 
at the site of absorption. The drugs which have local action or 
those  which  have  maximum  absorption  in  gastrointestinal 
tract (GIT) require increased duration of stay in GIT. Thus, 
mucoadhesive dosage forms are advantageous in increasing 
the drug plasma concentrations and also therapeutic activity. 
Mucoadhesive  drug  delivery  systems  facilitate  an  intimate 
contact  of  the  dosage  form  with the  underlying  absorption 
surface and thus improve the therapeutic performance of the 
drug. In recent years, many such mucoadhesive drug delivery 
systems have been developed for oral, buccal, nasal, rectal 
and vaginal routes for both systemic and local effects
1. 
Metformin  Hydrochloride  (MH)  is  an  oral  hypoglycaemic 
agent belongs to biguanides class.
2 MH has been reported to 
control  glucose  level  and  improve  lipid  profile  in  type-II 
diabetics.It has a short half‐life (1.5‐ 4.5 hours), so repeated 
administration (250mg twice or thrice daily) is required to 
maintain effective plasma concentrations. It is absorbed from 
upper  intestine  within  6  hours.  Administrations  of  a 
sustained‐  release,  once  a  day  Metformin  hydrochloride 
dosage form could reduce the dosing frequency and improve 
the patient compliance
3. Thus, in the present study, MH is 
selected as a model drug and SCMC, CMC, MC and PVP are 
chosen as a mucoadhesive polymer for design and evaluation 
sustained release microbeads. This study  was performed to 
investigate  the  mucoadhesion  and  sustaining  effect  of  co-
polymers  (SCMC,  CMC,  MC,  PVP)  on  metformin 
hydrochloride  release  from  the  sodium  alginate  beads 
adhered on the fresh goat stomach mucosa was studied.  
MATERIALS AND METHODS 
Metformin  Hcl  and  Sodium  carboxy  methyl  cellulose 
(SCMC)  was  a  gift  sample  from  Glukem  pharmaceuticals 
Pvt.Ltd  (Hyderabad,  India).  Sodium  alginate,  methyl 
cellulose (MC) and poly vinyl pyrollidone was obtained from 
Loba  chemie  Pvt.  Ltd  (Mumbai,  India).  Calcium  chloride 
obtained  from  Thermo  fisher  scientific  Pvt.  Ltd  (Mumbai, B. Samyuktha Rani et al. IRJP 2012, 3 (5) 
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India).  Carboxy  methyl  cellulose  (CMC)  obtained  from 
Merck specialities Pvt. Ltd (Mumbai, India).  
Method of preparation of mucoadhesive microbeads of 
metformin HCL 
Mucoadhesive microbeads of metformin HCL is prepared by 
ionotropic gelation technique by using different proportions 
of  sodium  alginate  and  co  -  polymer  (MC,  CMC,  SCMC, 
PVP)  ratio  as  indicated  in  Table  -1.  Initially  weigh  the 
required  amount  of  sodium  alginate  and  co-polymer 
dissolved in 100ml of water to get a uniform dispersion
4, 5. To 
the above dispersion add 200mg of the drug and mix it well. 
Then  obtained  dispersion  containing  sodium  alginate:  co-
polymer and drug is filled in the syringe with needle size of 
24 in to 10% w/v cacl2 solution drop by drop to get spherical 
micro beads. The added droplets were retained in the calcium 
chloride  solution  for  20  minutes  to  complete  the  curing 
reaction  and  to  produce  spherical  rigid  micro  beads.  The 
micro  beads  were  collected  and  dried  over  night  at  room 
temperature.  The  obtained  micro  beads  were  stored  in 
desiccators for further evaluation tests. 
In – vitro characterization of prepared microbeads 
Assay of metformin HCL 
A standard solution of metformin hydrochloride was prepared 
by dissolving 100 mg of the drug in 100 ml of distilled water 
and further diluted with water to get primary stock solution 
(1000 μg / ml). From the primary stock pipette out 1ml and 
make up to 100ml with water to get secondary stock solution 
(10 μg/ml). From this secondary  stock solution pipette out 
1ml  and  make  up  to  100ml  with  water  to  get  final  stock 
solution. From this final stock take1ml ,2ml, 3ml, 4ml, 5ml, 
6ml,  7ml, 8ml, 9ml,10ml in to ten volumetric flasks (100m.l 
capacity) for serial dilution. Finally make up with water upto 
mark. 
Micromeritic properties: 
Angle of repose (θ) 
The angle of repose of prepared micro beads was determined 
by glass funnel method, weigh required quantity of 2gm of 
the prepared using following equation
6. 
θ = tan
-1 h / r 
Where, 
θ = angle of repose 
h = height of the pile and 
r = radius of the powder cone 
Bulk density  
Bulk density of formulated micro beads was determined by 
taking a known mass of 2gm of formulated micro beads in a 
5 ml graduated measuring cylinder which is attached to the 
bulk density apparatus. The bulk density was calculated by 
following equation
6. 
Bulk density = Weight of micro beads in gram / Bulk volume 
of micro beads in cm
3 
Tapped density  
Tapped density  of micro beads was determined by tapping 
method using measuring cylinder containing weighed amount 
of 2gm of formulated micro beads. The cylinder was dropped 
three times from a height of one inch at an interval of two 
seconds.  Tapped density of microspheres was calculated by 
following equation
6. 
Tapped density =  Mass  of  micro  beads  /  Volume  of  micro 
beads after tapping 
Carr’s compressibility index  
This is an important property in maintaining uniform weight. 
It is calculated using following
6 
% Compressibility Index = Tapped density – Bulk density X 
100 / Tapped density 
Hausner’s ratio
  
Hausner’s ratio can be calculated by formula
6 
Hausner’s Ratio = Tapped Density X 100 / Bulk Density 
Particle size and its distribution  
The  particle  size  for  the  prepared  micro  beads  can  be 
measured  by  optical  microscope.  The  size  distribution 
analysis was done by sieving technique using standard sieves 
(16,  18,  20  and  25)  according  to  monograph.  Weighed 
quantity of 2gm of the formulated micro beads were placed 
on the coarsest sieve on the top and allow it for shaking for 
5min  using  mechanical  gyratory  shaker.  The  amounts 
retained on different sieves were weighed. The mean particle 
size of the microbeads was calculated by the formula
 7.   
Mean Particle Size = Σ (Mean Particle Size of the Fraction X 
Weight Fraction) / (Weight Fraction)                                                  
Swelling study  
The swelling index of the formulated beads was carried out in 
10ml water and simulated bio- fluids (pH 1.2 and pH 7.4). 
Drug loaded beads were equilibrated in different test tubes at 
37ºC  for  12hrs  hours.  The  test  tubes  were  withdrawn  at 
different  intervals;  the  beads  were  filtered  and  transferred 
into a small beaker and then weigh. Swelling index can be 
calculated by the formula
8. 
Swelling index = Wt – W 0 X 100 / W 0 
Where,  
Wt = weight of micro beads observed at 8
th hr 
W 0 = the initial weight of micro beads  
Percentage drug content and encapsulation efficiency  
100 mg of accurately weighed formulated micro beads were 
dissolved  in  100ml  distilled  water  until  get  dissolved 
completely. Filter the solution and take 0.5 ml of aliquot and 
make the suitable dilution to get 5µg / ml and analyzed for 
the  drug  content  at  233nm  wavelength  against  blank. 
Percentage drug content was calculated by 
7 
Drug Content (mg) = (Absorbance × Slope ± Intercept) × 
Dilution factor / 1000 
It gives drug content for 100 mg of micro beads  from that 
calculate drug content for total quantity of micro beads , from 
actual drug content, the value of encapsulation efficiency was 
determined using the formula given below. 
Encapsulation efficiency = Actual drug content x 100 / 
Theoretical drug content                                          
In – vitro Drug Release Studies 
The release rate of drug from the prepared micro beads was 
determined  using  United  States  Pharmacopeia  (USP) 
Dissolution  testing  apparatus  I  (basket  method).  The 
dissolution test was performed using 900 ml of pH 1.2 HCL 
buffer  for  8hrs.  A  sample  (5  ml)  of  the  solution  was 
withdrawn  from  the  dissolution  apparatus  hourly  and  the 
samples were replaced with fresh dissolution medium. The 
samples were filtered through a 0.45μ membrane filter and 
diluted  to  a  suitable  concentration  with  of  pH  1.2  HCL 
buffer.  Absorbance  of  these  solutions  was  measured  at 
233nm using a UV/Visible spectrophotometer. 
Mucoadhesion testing by in- vitro wash- off method 
 
The  goat  stomach  mucosa  was  used  for  in  –  vitro
 
mucoadhesion evaluation. The mucosa was removed and cut 
in to pieces 2cm long and 2cm wide and were rinsed with 
2ml  of  0.1N  Hcl  (pH 1.2).  100microbeads  of  each  were 
scattered uniformly on the surface of the stomach mucosa. 
After 20 minutes, the tissue was taken out and fixed on a 
polyethylene support at an angle 45
0. About 100 micro beads 
were  spread  on  to  each  wet  rinsed  tissue  specimen  and 
immediately thereafter the support was hung on to the arm of 
a USP tablet disintegrating test machineas shown in Figure-1. B. Samyuktha Rani et al. IRJP 2012, 3 (5) 
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When the disintegrating test machine was operated, the tissue 
specimen was given a slow, regular up- and down movement 
in  the  test  fluid  at  37
0C  contained  in  a  1L  vessel  of  the 
machine. At one end of 30minutes, at the end of 1hr, and at 
hourly intervals up to 8hrs the machine was stopped and the 
number  of  micro  beads  still  adhering  to  the  tissue  was 
counted
9.
 
Fourier Transform- Infrared Spectroscopic Analysis (FT-
IR) 
Drug  polymer  interactions  were  studied  by  FT-IR 
spectroscopy. One to 2mg of pure drug, placebo microbeads, 
and  drug  loaded  microbeads  samples  were  weighed  and 
mixed  properly  with  potassium  bromide  to  a  uniform 
mixture. A small quantity of the powder was compressed into 
a thin semitransparent pellet by applying pressure. The IR- 
spectrum  of  the  pellet  from  450-  4000cm
-1  was  recorded 
taking  air  as  the  reference  and  compared  to  study  any 
interference
10.  
RESULTS AND DISCUSSION  
All  the  micromeritic  properties  for  the  prepared  twenty 
formulations were performed, that are bulk density, tapped 
density, hausner’s ratio, compressibility index and angle of 
repose as per the I.P and these properties for all the prepared 
twenty formulations as shown in Table - 2 were within the 
limits.  Particle  size  and  its  size  distribution  were  done  by 
optical  microscopy  and  sieve  analysis  method.  Results 
revealed  that  the  particle  size  was  more  for  the  M5 
formulation  as  indicated  in  Table-3  compared  to  other 
prepared  formulation  this  was  because  of  the  fact  that  by 
increasing the polymer concentration results in enhanced the 
viscosity  of  the  preparation  which leads  to  increase  in  the 
emulsion drop size and finally results in increase the particle 
size of the microbeads as shown in Figure- 2. Swelling index 
data  for  all  the  prepared  formulations  were  done  and  M5 
formulation shows the maximum swelling index of 85% for 8 
hrs  in  pH  1.2HCL.  Swelling  index  was  increased  with 
increase in the co-polymer concentration (Table – 4). Results 
showed that the swelling index for sodium carboxy methyl 
cellulose formulations was high due to high gelling character 
when  compared  to  other  formulations  containing  co- 
polymers as represented in Figure -3. Results also concluded 
that poly vinyl pyrrolidone had the low swelling index due to 
its  low  capacity  to  form  the  gel.  Drug  content  and 
encapsulation efficiency were calculated for all the prepared 
formulations (Table-5). Results showed that formulation M5 
exhibit  more  encapasulation  efficiency  and  M16  exhibits 
lesser encapsulation efficiency compared to all other prepared 
formulations. Increase in the co-polymer concentration leads 
to increase in the percentage drug content. And the results 
showed that the percentage drug content and encapsulation 
efficiency  for  sodium  carboxy  methyl  cellulose  containing 
formulations  was  high  due  to  high  gelling  property  when 
compared to other formulations containing co- polymers were 
as poly  vinyl pyrrolidone containing  formulations had the 
low  percentage  Drug  content  and  encapsulation 
efficiency(Figure - 4, 5). The drug release profiles of the drug 
from the prepared formulations were shown in Table-6 and 
figure – 6 (a, b), 7, 8 and 9. the mucoadhesive microbeads 
prepared with SCMC (sodium carboxy methyl cellulose) as 
co-polymer  has  good  drug release  profile  of  79%  for  7hrs 
(M5)  when  compared  to  other  formulations  containing 
varying proportions of sodium alginate  as a main polymer 
and co- polymers. This was due to  the fact that by increasing 
the density of polymer matrix at high concentration results in 
an  increase  in  diffusional  path  length.This  may  finally 
decrease the drug release from polymer matrix. Finally it was 
concluded that all the hydrophyllic co- polymers which were 
used  for  the  study  provides  the  sustained  release 
mucoadhesive microbeads of metformin HcL as per the limits 
according to the USP. The mucoadhesive property for sodium 
carboxy methyl cellulose was high as indicated in Table – 7 
and shown in Figure- 10 due to high swelling index and the 
mucoadhesive property for poly vinyl pyrrolidine was low. It 
was concluded that the mucoadhesive property increases by 
increasing  the  copolymer  concentration.  From  the  data  of 
drug  release,  it  was  found  that,  all  the  mucoadhesive 
microbead formulations follow diffusion mechanism for the 
drug release. The Higuchi square root equation describes the 
release from systems where the solid drug is incorporated in 
the beads and the rate of drug release is related to the rate of 
drug diffusion. FT-IR spectra of Metformin HCL , Sodium 
alginate : PVP , Sodium alginate : SCMC, Sodium alginate : 
CMC, Sodium alginate : MC (1:1) & prepared formulations 
were  recorded.  The  Metformin  HCL  present  in  the 
formulations  M1,  M6,  M11,M16  was  confirmed  by  FT-  IR 
(Figure  11-19).  No  predominant  drug  interaction  was 
detected .The region 3600-3200cm
-1 was a stretching region 
of  the  functional  group  (N-H),  2820-2780  cm
-1  (N-CH3), 
1680- 1620 cm
-1 (C=C), 1652-1550 cm
-1 (C=NH), 1190-1130 
cm
-1(  C≡N).  All  These  Peaks  were  appeared  in  pure 
metformin HCL and all prepared formulations indicating no 
drug interactions between drug and excipients. All the spectra 
which were obtained from the polymer and the co- polymer 
were studied and it was found that there was no interaction 
between main polymer and co- polymers. 
CONCLUSION  
The  study  was  undertaken  with  the  aim  to  formulate  and 
evaluate the sustained release mucoadhesive microbeads of 
Metformin Hcl using sodium alginate as polymer and SCMC, 
CMC, MC, PVP as co- polymers. The microbeads have been 
utilized  to  obtain  prolonged  and  uniform  release  in  the 
stomach for development of a once daily formulation. In the 
present  study,  preparation  of  metformin  hydrochloride 
microbeads, evaluation of Drug Delivery System (DDS) in 
vitro, prediction of the release, and drug release pattern to 
match  target  release  profile  was  investigated.  Microbeads 
were  prepared  by  Ionotropic  gelation  method  using 
SCMC,CMC, MC and PVP as the rate controlling polymer 
and 200 mg of metformin hydrochloride per batch and it’s in- 
vitro performance was evaluated by the usual pharmacopoeia 
and other tests such as, Drug polymer compatibility (FT-IR 
scan),Yield  (%),  Particle  size  analysis,  Drug  entrapment 
efficiency, In - vitro release studies. Where the polymer ratio 
increases,  the  particle  size  may  also  increases,  thus 
entrapment efficiency increases, hence the release profile was 
extended. The adhesion of microbeads to the stomach mucosa 
of  goat  was  evaluated  as  the  mean  percent  of  microbeads 
remain  adhered  after  defined  period  of  washing.  Results 
indicating  that  the  polymer  to  drug  ratio  had  a  significant 
effect on mucoadhesive property. From the above study it has 
been noticed that as the concentration of copolymer (SCMC, 
CMC,  MC  and  PVP)  associated  with  the  main  polymer 
increases,  mucoadhesive  property  increases  and  when  the 
concentration  of  the  main  polymer  (sodium  alginate) 
increases,  the  mucoadhesive  property  of  the  microbeads 
decreases.  The  developed  Microbeads  of  metformin 
hydrochloride  may  be  used  in  clinical  for  prolonged  drug 
release in stomach for at least 8 hrs, thereby improving the 
bioavailability and patient compliance. 
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Table 1: Development of Different Formulations Containing, Varying Proportions of Polymer 
Formulation 
code 
Drug 
(mg) 
CaCl2 
 (%w/ 
v) 
Sodium 
alginate (gm) 
 
Sodium Carboxy 
methyl cellulose 
(SCMC) 
(gm) 
Carboxy Methyl 
cellulose 
(CMC) 
(gm) 
Methyl 
cellulose 
(MC) 
(gm) 
Poly vinyl 
pyrollidone 
(PVP) 
(gm) 
M1  200  10  1  1  -  -  - 
M2  200  10  3  1  -  -  - 
M3  200  10  5  1  -  -  - 
M4  200  10  1  3  -  -  - 
M5  200  10  1  5  -  -  - 
M6  200  10  1  -  1  -  - 
M7  200  10  3  -  1  -  - 
M8  200  10  5  -  1  -  - 
M9  200  10  1  -  3  -  - 
M10  200  10  1  -  5  -  - 
M11  200  10  1  -  -  1   
M12  200  10  3  -  -  1  - 
M13  200  10  5  -  -  1  - 
M14  200  10  1  -  -  3  - 
M15  200  10  1  -  -  5  - 
M16  200  10  1  -  -  -  1 
M17  200  10  3  -  -  -  1 
M18  200  10  5  -  -  -  1 
M19  200  10  1  -  -  -  3 
M20  200  10  1  -  -  -  5 
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Table 2: Micromeritic Properties of Various Prepared Formulations 
Formulation code  Bulk density 
(gm / cc) 
Tapped density 
(gm / cc) 
Hausner’s ratio  Compressibility 
index (%) 
Angle of repose (θ) 
M1  0.40 ± 0.01  0.44 ± 0.01  110  ± 1.52  19  ± 0.52  19.13  ±0.15 
M2  1.0 ± 0.10  1.0 ± 0.10  100  ± 1.52  24. 2  ± 0.50  24.22  ±0.30 
M3  0.57 ± 0.10  0.66 ± 0.01  115.7  ± 0.26  13.6  ± 1.0  22.78  ±0.35 
M4  0.66 ± 0.01  0.66 ± 0.01  100  ± 1.0  20  ± 1.05  21.80 ±0.49 
M5  0.66 ± 0.01  0.8±0.10  121.2  ± 0.64  17.5  ± 1.00  26.56 ±0.45 
M6  0.5 ± 0.10  0.6 ± 0.10  132  ± 1.0  24.4  ± 1.0  10.08±0.05 
M7  0.8 ± 0.10  1.0 ± 0.15  125  ± 1.0  20  ± 1.0  12.40  ±0.26 
M8  0.66  ± 0.01  0.66 ± 0.1  100  ± 1.0  13.6  ± 0.50  19.79  ±0.45 
M9  0.30 ±  0.01  0.36 ± 0.01  120  ± 1.0  16.6  ± 0.57  21.80  ±0.47 
M10  0.23 ± 0.01  0.26±0.01  113.0  ± 0.45  11.53  ± 1.0  21.80  ±0.47 
M11  0.5 ± 0.07  0.5 ± 0.10  100 ± 1.0  20 ± 1.0  09.46±0.01 
M12  0.66 ± 0.07  1.00 ± 0.10  151.5 ± 0.75  34 ±1.0  11.39  ±0.15 
M13  0.5 ± 0.10  0.66 ± 0.10  132  ± 1.52  24.4  ± 0.088  12.407 ±0.1 
M14  0.5±  0.10  0.66 ± 0.01  132  ± 1.0  24.4  ± 1.01  19.76  ±0.32 
M15  0.5 ± 0.10  0.5 ± 0.17  100  ± 1.0  24.4  ±  1.0  30.96  ±0.40 
M16  0.66 ± 0.01  0.66±0.01  100  ± 1.52  21.2  ± 1.1  16.69  ±0.20 
M17  0.66 ± 0.01  1.0±0.01  100  ± 1.52  34  ± 1.52  19.79  ±0.2 
M18  0.8 ± 0.015  1.0±0.10  125 ±1.0  20  ± 0.56  15.10  ±0.1 
M19  0.33 ± 0.01  0.33 ± 0.15  100  ± 1.52  24.2  ± 0.43  20.30  ±0.25 
M20  0.25 ± 0.01  0.33 ± 0.01  132  ± 1.52  24.2  ± 0.43  23.74  ±0.36 
 
Table 3: Particle Size and Size Distribution of Various Prepared Formulations 
Formulation code  Particle size (µm)  Size distribution (µm) 
M1  1150±2.0  1161.70 ±0.36 
M2  1310±2.60  1172.7 ±0.36 
M3  1370±1.52  1178.6 5 ±0.32 
M4  1510±2.08  1179.10 ±0.26 
M5  1530±1.52  1180 ±0.15 
M6  1170±1.52  1158.92 ±0.45 
M7  1190±1.52  1161.47 ±0.15 
M8  1220±2.64  1177.30 ±0.15 
M9  1260±1.0  1180 ±0.15 
M10  1280±2.51  1180 ±0.25 
M11  710± 1.52  929.75 ± 0.36 
M12  880±1.0  1149.72 ±0.36 
M13  970±2.08  1180 ±1.0 
M14  1160±2.51  1180 ±1.0 
M15  1320±2.51  1250.4 ±0.30 
M16  720±2.0  781.32 ±0.15 
M17  850±0.57  1086.55 ±0.4 
M18  1320±1.52  1175.65 ±0.3 
M19  1360±2.08  1180 ±0.1 
M20  1430±1.0  1180 ±0.26 
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Table 4: Swelling Study of Various Prepared Formulation 
Formulation code  Swelling index (using pH 1.2HcL) in time intervals (hr) 
  1
sthr  2
ndhr  3
rdhr  4
thhr  5
thhr  6
thhr  7
thhr  8
thhr 
M1  51  54  56  59  63  71  74  79 
M2  46  48  51  56  59  63  69  74 
M3  49  50  53  58  60  68  70  76 
M4  54  56  59  61  67  75  79  81 
M5  56  61  67  69  73  77  82  85 
M6  50  53  55  58  61  69  71  77 
M7  45  46  49  51  57  60  66  71 
M8  47  49  51  56  58  64  67  74 
M9  53  54  57  60  66  74  78  80 
M10  55  60  65  68  71  75  80  83 
M11  49  81  53  56  60  67  70  75 
M12  43  45  47  49  56  60  65  69 
M13  45  46  49  54  56  61  66  71 
M14  51  53  55  59  64  73  77  79 
M15  53  58  63  67  70  73  79  81 
M16  35  46  51  54  58  66  69  71 
M17  31  42  47  48  51  58  61  67 
M18  29  39  44  46  51  56  63  69 
M19  46  51  54  57  61  69  74  76 
M20  49  53  59  61  67  70  73  77 
 
Table 5:  Percentage Drug content and Encapsulation Efficiency of Various Prepared Micro Bead Formulation 
Formulation code  % Drug content  % Encapsulation efficiency 
M1  0.68±0.05  69.12±0.37 
M2  1.37±0.01  77.56±0.50 
M3  1.54±0.01  78.76±0.41 
M4  1.37±0.08  87.59±0.55 
M5  2.40±0.05  90.09±0.58 
M6  1.20±0.06  47.20±0.30 
M7  2.40±0.06  58.69±0.25 
M8  1.02±0.05  63.52±0.40 
M9  0.68 ± 0.5  71.59±0.30 
M10  2.40 ± 0.1  86.41±0.70 
M11  0.51±0.02  51.89±0.58 
M12  0.85±0.04  68.80±0.30 
M13  1.02±0.02  73.71±0.51 
M14  1.37±0.05  77.15±0.81 
M15  1.37±0.05  86.07±0.46 
M16  0.68±0.11  37.13±0.88 
M17  0.85±0.03  43.67±0.05 
M18  0.85±0.05  56.19±0.58 
M19  1.20±0.18  74.47±0.20 
M20  2.05±0.03  79.27±0.32 
 
Table 6(a):  Cumulative Percentage Drug Release of Various Prepared Micro Bead Formulations (M1 - M10) 
Time 
(min) 
Formulation code and its Cumulative % drug release 
M1  M2  M3  M4  M5  M6  M7  M8  M9  M10 
15  5.445  5.14  4.95  5.54  5.84  5.39  5.049  4.99  5.54  5.59 
30  10.99  10.72  9.99  11.23  12.19  10.33  10.14  10.04  11.11  12.15 
45  15.62  16.11  15.78  15.97  19.13  16.29  15.11  15.19  16.92  19.17 
60  20.45  21.51  23.30  22.81  26.92  22.90  20.36  20.24  22.51  26.17 
120  26.23  28.45  28.51  28.59  34.98  28.44  25.55  25.44  28.50  33.49 
180  32.11  29.305  33.96  34.63  43.70  34.26  31.75  30.69  34.52  40.97 
240  42.16  33.84  39.90  47.67  51.34  40.47  36.39  36.03  40.56  48.93 
300  51.44  39.43  45.15  57.56  67.40  46.72  41.79  41.43  46.50  55.13 
360  61.24  45.11  51.17  60.90  70.52  60.97  56.19  54.79  61.75  64.15 
420  69.88  61.21  57.71  71.10  79.55  70.77  70.58  68.25  70.95  72.51 
 
Table 6(b):  Cumulative Percentage Drug Release of Various Prepared Micro Bead Formulations 
(M11 – M20) 
Time 
(min) 
Formulation code and its Cumulative % drug release 
M11  M12  M13  M14  M15  M16  M17  M18  M19  M20 
15  4.900  4.851  4.75  4.95  5.49  4.85  4.75  4.65  4.95  5.44 
30  9.85  9.75  9.60  10.04  11.03  9.85  9.60  9.40  9.94  10.93 
45  14.99  14.80  14.75  15.19  18.90  14.89  14.55  14.25  15.04  18.31 
60  20.19  19.89  19.70  21.13  25.98  19.99  19.55  19.20  20.19  25.74 
120  25.39  25.04  24.79  27.17  33.11  25.14  24.60  24.25  25.39  33.01 
180  30.73  30.24  29.94  33.25  40.34  30.39  29.7  29.35  30.64  40.34 
240  36.67  35.49  35.24  39.39  48.00  35.73  37.84  34.50  35.89  47.71 
300  42.66  40.78  40.59  45.58  51.82  41.13  40.04  39.66  41.28  48.16 
360  58.01  56.18  55.93  60.43  61.82  55.98  54.74  54.30  56.23  58.01 
420  68.90  67.02  66.67  70.33  71.87  68.70  65.98  65.43  71.23  71.62 
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Table 7: Mucoadhesive Test Data for Various Prepared Formulations 
Formulation code  Mucoadhesive test in time (min) for  100 beads 
 
60  120  180  240  300  360  420  480 
M1  80  72  63  55  43  32  30  29 
M2  92  81  77  72  69  66  64  63 
M3  94  90  87  84  82  77  74  72 
M4  95  92  90  87  85  83  80  79 
M5  97  95  93  90  85  84  80  80 
M6  75  71  69  54  42  30  29  26 
M7  90  83  74  62  55  52  50  49 
M8  92  82  73  72  66  62  60  55 
M9  94  86  73  70  65  63  61  57 
M10  95  88  82  79  75  73  70  68 
M11  88  82  77  72  65  48  36  27 
M12  90  81  75  66  61  56  49  43 
M13  93  88  85  81  74  72  65  52 
M14  92  84  81  78  76  65  61  53 
M15  93  92  81  78  72  69  67  64 
M16  75  60  55  41  37  35  28  22 
M17  80  87  73  68  65  53  42  35 
M18  83  80  75  71  63  59  55  52 
M19  91  87  82  80  76  71  68  50 
M20  90  84  80  77  74  73  60  61 
 
 
Figure 1: Mucoadhesive Test for Prepared Formulation 
 
 
Figure 2:  Optical Microscopic View of Various Prepared Formulations 
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Figure 3: Swelling Study Data of Various Prepared Formulations 
 
 
Figure 4: Encapsulation Efficiency Data of Various Prepared Formulations 
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Figure 5: Drug Content data of Various Prepared Formulations 
 
 
Figure 6: Percentage Drug Release of Formulations Containing Sodium Alginate: Sodium Carboxy Methyl Cellulose at Various Time Intervals 
 
 
Figure 7: Percentage Drug Release of Formulations Containing Sodium Alginate: Carboxy Methyl Cellulose at Various Time Intervals 
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Figure 8: Percentage Drug Release of Formulations Containing Sodium Alginate:  Methyl Cellulose at Various Time Intervals 
 
 
Figure 9: Percentage Drug Release of Formulations Containing Sodium Alginate:  Poly Vinyl Pyrrolidone at Various Time Intervals 
 
 
Figure10: Mucoadhesive test data for various prepared formulations B. Samyuktha Rani et al. IRJP 2012, 3 (5) 
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Figure 11and12: FT – IR Spectra For Sodium Alginate: PVP (1:1) and Sodium Alginate: CMC (1:1) 
   
Figure 13 and 14: FT – IR Spectra for Sodium Alginate: SCMC   (1:1) and Sodium Alginate: MC   (1:1) 
 
 
Figure 15: FT – IR Spectra for pure drug (Metformin hydrochloride) 
 
   
Figure 16 and 17: FT – IR Spectra for M11 Formulation and M6 Formulation 
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Figure 18 and 19: FT – IR Spectra for M1 Formulation and M16 Formulation 
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